Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study

Cephalalgia 2024 Aug;44(8):3331024241274343.  doi: 10.1177/03331024241274343. Zaza Katsarava, Dawn C Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S Matharu, Aubrey Manack Adams, Karen Carr, Kristina M Fanning, Richard B Lipton Abstract Background: Few studies of migraine have evaluated migraine disability across multiple countries using the same methodology. Methods: This cross-sectional, web-based

Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study

The journal of headache and pain 2024 Aug 19;25(1):134. doi: 10.1186/s10194-024-01834-y. Michel Lanteri-Minet, Elizabeth Leroux, Zaza Katsarava, Richard B Lipton, Fumihiko Sakai, Manjit Matharu, Kristina Fanning, Aubrey Manack Adams, Katherine Sommer, Michael Seminerio, Dawn C Buse Abstract Objective: To assess rates of traversing barriers to care to access optimal clinical outcomes

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial

Neurology 2024 Jul 23;103(2):e209584.  doi: 10.1212/WNL.0000000000209584. Epub 2024 Jun 26. Peter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, Genevieve Demarquay, Sait Ashina, Fumihiko Sakai, Brian Neel, Pranav Gandhi , Brett Dabruzzo, Jonathan H Smith, Yingyi Liu, Joel M Trugman Abstract Background and objectives: Atogepant is an oral, calcitonin gene-related peptide receptor antagonist approved

Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study

Neurology 2024 May;102(10):e209349.  doi: 10.1212/WNL.0000000000209349. Epub 2024 Apr 26. Uwe Reuter, Peter J Goadsby, Michel D Ferrari, Gabriel Paiva Da Silva Lima, Subhayan Mondal, Jawed Kalim, Fatima Hasan, Shihua Wen, Michal Arkuszewski, Shaloo Pandhi, Tracy Stites, Michel Lanteri-Minet    Abstract Background and objectives: The LIBERTY study assessed the efficacy and safety of erenumab

Patient Sex in Prescribing CGRP Receptor Antagonists for Migraine

JAMA Neurology JAMA Neurol. Published online February 26, 2024. doi:10.1001/jamaneurol.2023.5835 Michel Lanteri-Minet; Shuu-Jiun Wang; Paolo Martelletti To the Editor In a recent JAMA Neurology Viewpoint,1 Porreca and Dodick raised an important issue by discussing gender differences in outcomes of calcitonin

Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial

The Lancet Neurology 2024 Feb 13:S1474-4422(24)00025-5. doi: 10.1016/S1474-4422(24)00025-5.  Cristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, Michel Lanteri-Minet, Sara Sacco, Tomáš Nežádal, Hua Guo, Rosa De Abreu Ferreira, Giovanna Forero, Joel M Trugman Abstract Background: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of

Generalizability of clinical trial efficacy results to a real-world population: An example in migraine prevention

The Journal of managed care and specialty pharmacy 2023 Dec;29(12):1321-1330.doi: 10.18553/jmcp.2023.29.12.1321. Marie-Ange Paget, Antje Tockhorn-Heidenreich, Mark Belger, Florence Chartier, Michel Lantéri-Minet Abstract Background: Health care decision makers are often concerned about the external validity of randomized controlled trials (RCTs), as their results may not